AI to Design Gene Therapy Carriers for Cystic Fibrosis Patients

The Cystic Fibrosis Foundation announced on September 10, 2026 an investment of up to $7.3 million in Boston-based startup Ride Therapeutics. The funding will support development of a platform in which artificial intelligence learns to design nanoparticles capable of delivering gene therapy to the lung cells of people with cystic fibrosis - a problem that has held back this branch of medicine for years.

The drug delivery problem

Gene therapies for cystic fibrosis are nothing new - scientists have been testing them for decades, trying to introduce a correct copy of the CFTR gene into lung epithelial cells. The trouble lies elsewhere: the thick, sticky mucus that builds up in patients' airways effectively blocks carriers, whether modified viruses or lipid nanoparticles, from reaching the right cells.

Previous approaches relied mainly on trial and error in the lab, testing individual carrier variants and slowly iterating their composition. Ride Therapeutics wants to speed this up by turning the process into a feedback loop between experiment and algorithm.

How Molecular Logistics works

The company's platform creates highly diverse libraries of millions of nanoparticles, varying in size, composition and the type of cargo carried, from RNA molecules to larger genetic constructs. After these particles are administered (intravenously or by inhalation), researchers track which tissues and cell types they actually reach.

These experiments generate billions of data points used to train a generative AI model. The system's task is to identify the physicochemical traits shared by the most effective carriers, then design new candidates tailored to a specific tissue, in this case lung epithelium. The company stresses that the AI plays no diagnostic or therapeutic role; it is solely a tool for accelerating carrier design.

The promise of gene therapies has never been greater, but it can only be realized by solving the problem of delivering the drug to its target - Sam Cohen, co-founder and CEO of Ride Therapeutics

Who is behind the project

Ride Therapeutics was founded in 2023 as a spin-off from Harvard University and Cambridge, with an $8 million seed round. The company's scientific co-founders include professors David Weitz and Tuomas Knowles, researchers specializing in materials engineering and molecular biophysics.

The new funding from the Cystic Fibrosis Foundation is intended to let the company build on its existing work on intravenous drug delivery and extend the technology to an inhaled version that reaches the lungs directly, the natural route of administration for cystic fibrosis treatment.

Why it matters for some patients

In recent years, treatment of cystic fibrosis has been transformed by CFTR modulators such as Trikafta, which improve the function of the defective protein in most patients. The problem is that 10 to nearly 20 percent of patients have mutations for which these drugs don't work or are poorly tolerated - this is the group gene therapies are primarily aimed at, since no causal therapy currently exists for them.

The Cystic Fibrosis Foundation is not the only organization funding AI work on gene therapy delivery - around the same time, the foundation also backed a smaller project by Nanite, which is developing the SAYER platform combining automated polymer synthesis with machine learning. This shows that the problem of getting a drug into the cell has become one of the funding priorities in cystic fibrosis research, alongside gene therapies themselves.

What's next

Ride Therapeutics' project is at an early, preclinical stage - the announcement gives no timeline for first human trials or specific lab results. This is research into a design tool, not a finished therapy, so for now it changes nothing in patients' day-to-day treatment.

For Polish patients and clinicians following progress in cystic fibrosis gene therapies, what matters most is how quickly AI platforms like this one can shorten the years-long cycles of trial and error involved in designing carriers - it is this stage, not the gene therapy itself, that has so far been the field's main bottleneck.